Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany.
J Cardiothorac Vasc Anesth. 2010 Jun;24(3):394-8. doi: 10.1053/j.jvca.2009.09.014. Epub 2009 Dec 11.
Preparing hydroxyethyl starch (HES) in a plasma-adapted solution is supposed to improve safety with regard to coagulation. The influence of a new plasma-adapted HES preparation on coagulation was studied.
Operator-blinded, randomized study.
Laboratory in vitro study.
Fifteen healthy young men scheduled for blood donation.
Blood was diluted by 10%, 30%, and 50% using either a plasma-adapted or nonplasma-adapted (prepared in saline solution) potato-derived 6% HES 130/0.42. Only the composition of the solvent of the 2 HES preparations was different.
Rotation thromboelastometry (ROTEM; Pentapharm, Munich, Germany) was used to assess changes in coagulation; whole blood aggregometry with 3 inducers was used to assess effects of dilution with HES on platelet function. Clotting time (CT) and clot formation time were significantly prolonged by 30% and 50% dilution, showing significantly longer times in the non-plasma-adapted than in the plasma-adapted HES group (eg, intrinsic CT at the 30% dilution level: plasma-adapted HES 228 +/- 26 seconds [within normal range] v 269 +/- 29 seconds in the nonplasma-adapted HES group). Clot strengthening and clot firmness were significantly reduced by the non-plasma-adapted HES at the 30% dilution level. Platelet aggregation was significantly more reduced by the non-plasma-adapted HES at the 30% and 50% dilution levels.
Dilution with the nonplasma-adapted HES 130/0.42 was associated with more negative effects on thromboelastometry and platelet aggregation than the same HES 130/0.4 dissolved in a plasma-adapted solution. The benefits of using a plasma-adapted modern HES preparation on blood loss and use of blood/blood products in cardiac surgery need to be studied.
将羟乙基淀粉(HES)制备在血浆适应溶液中,据称可以改善凝血安全性。本研究旨在研究一种新的血浆适应型 HES 制剂对凝血的影响。
操作者设盲、随机研究。
体外实验室研究。
15 名计划献血的健康年轻男性。
通过用血浆适应或非血浆适应(在生理盐水溶液中制备)马铃薯衍生的 6% HES 130/0.42 分别稀释 10%、30%和 50%的血液。两种 HES 制剂的溶剂组成仅不同。
使用旋转血栓弹性测定法(ROTEM;Pentapharm,慕尼黑,德国)评估凝血变化;使用 3 种诱导剂的全血聚集测定法评估 HES 稀释对血小板功能的影响。30%和 50%稀释均显著延长凝血时间(CT)和凝块形成时间,非血浆适应型 HES 组的时间显著长于血浆适应型 HES 组(例如,内在 CT 在 30%稀释水平:血浆适应型 HES 228 +/- 26 秒[在正常范围内]比非血浆适应型 HES 组的 269 +/- 29 秒)。在 30%稀释水平,非血浆适应型 HES 显著降低凝块强化和凝块硬度。在 30%和 50%稀释水平,非血浆适应型 HES 显著降低血小板聚集。
与相同的 HES 130/0.4 溶解在血浆适应溶液中相比,用非血浆适应型 HES 130/0.42 稀释会对血栓弹性测定和血小板聚集产生更大的负面影响。需要研究在心脏手术中使用血浆适应型现代 HES 制剂对失血和血液/血液制品使用的益处。